Table 1.
Baseline demographic, clinical and treatment characteristics of patients with 2018 FIGO stage IB3-IIIC1 cervical cancer treated with pelvic radiation therapy with or without concurrent chemotherapy
| Characteristic | Number of patients | Percentage of patients |
|---|---|---|
| Age (years) | ||
| Median | 52 (range, 26-88) | |
| < 65 | 508 | 88.8% |
| ≥ 65 | 64 | 11.2% |
| Histology | ||
| Squamous cell carcinoma | 506 | 88.5% |
| Adenocarcinoma | 52 | 9.1% |
| Adenosquamous cell carcinoma | 10 | 1.7% |
| Others | 4 | 0.7% |
| 2018 FIGO stage | ||
| IB3 | 35 | 6.1% |
| IIA | 50 | 8.7% |
| IIB | 335 | 58.6% |
| IIIA | 18 | 3.1% |
| IIIB | 39 | 6.8% |
| IIIC1 | 95 | 16.6% |
| Primary tumor size | ||
| < 4 cm | 227 | 39.7% |
| ≥ 4 cm | 345 | 60.3% |
| Tumor extension to the pelvic wall* | ||
| Yes | 48 | 8.4% |
| No | 524 | 91.6% |
| Common iliac MLNs | ||
| Yes | 5 | 0.9% |
| No | 567 | 99.1% |
| Bilateral pelvic MLNs | ||
| Yes | 37 | 6.5% |
| No | 535 | 93.5% |
| Number of pelvic MLNs | ||
| 0 | 477 | 83.4% |
| 1 | 51 | 8.9% |
| 2 | 36 | 6.3% |
| ≥ 3 | 8 | 1.4% |
| Large pelvic MLNs (≥ 1.5 cm) | ||
| Yes | 541 | 94.6% |
| No | 31 | 5.4% |
| Concurrent chemotherapy | ||
| Yes | 484 | 84.6% |
| No | 88 | 15.4% |
Abbreviations: MLNs = metastatic lymph nodes;
* Tumor extension to the pelvic wall was diagnosed with gynecological examination.